Publicacións en colaboración con investigadores/as de Eli Lilly and Company (11)

2023

  1. Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits

    Nature Communications, Vol. 14, Núm. 1

  2. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

    The Lancet Diabetes and Endocrinology, Vol. 11, Núm. 1, pp. 33-41

2022

  1. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

  2. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

    The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824

2020

  1. A reference map of potential determinants for the human serum metabolome

    Nature, Vol. 588, Núm. 7836, pp. 135-140

  2. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810

2019

  1. Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration

    Journal of Hepatology, Vol. 71, Núm. 3, pp. 594-602

2015

  1. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy Epidemiology of musculoskeletal disorders

    BMC Musculoskeletal Disorders, Vol. 16, Núm. 1

2007

  1. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial

    Lancet Oncology, Vol. 8, Núm. 3, pp. 219-225

2005

  1. Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial

    Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 433-438